Elevation Oncology Inc
NASDAQ:ELEV

Watchlist Manager
Elevation Oncology Inc Logo
Elevation Oncology Inc
NASDAQ:ELEV
Watchlist
Price: 0.365 USD -2.12% Market Closed
Market Cap: $21.6m

Elevation Oncology Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Elevation Oncology Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Elevation Oncology Inc
NASDAQ:ELEV
Research & Development
-$28.6m
CAGR 3-Years
-7%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Elevation Oncology Inc
Glance View

Market Cap
21.6m USD
Industry
Biotechnology

Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

ELEV Intrinsic Value
HIDDEN
Show

See Also

What is Elevation Oncology Inc's Research & Development?
Research & Development
-28.6m USD

Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's Research & Development amounts to -28.6m USD.

What is Elevation Oncology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-40%

Over the last year, the Research & Development growth was -12%. The average annual Research & Development growth rates for Elevation Oncology Inc have been -7% over the past three years , -40% over the past five years .

Back to Top